EODData

MEMBERSHIP REGISTER LOG IN

FRA, 30S: SANIONA AB (PUBL)

16 Oct 2026
LAST:

0.8620

CHANGE:
 0.02		OPEN:
0.8620		HIGH:
0.8620		ASK:
0.0000		VOLUME:
0
CHG(%):
2.31		PREV:
0.8425		LOW:
0.8620		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
16 Oct 260.86200.86200.86200.86200
15 Oct 260.84250.84250.84250.84250
13 Oct 260.77600.89700.77600.89700
12 Oct 260.82450.82450.82450.82450
08 Oct 260.77950.77950.77950.77950
07 Oct 260.79550.79550.77950.77950
06 Oct 260.82150.82150.82150.82150
05 Oct 260.82050.82050.82050.82050
02 Oct 260.80750.81950.80750.81950
01 Oct 260.83050.83050.80550.80550

PROFILE

Name:SANIONA AB (PUBL)
About:Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder. It also develops SAN903, a novel medicine based on inhibition of the calcium-activated potassium ion channel, which has completed preclinical development for the treatment of inflammatory bowel disease; SAN2219, a subtype selective positive allosteric modulator of GABAA a2- a3- and a5 that is in preclinical stage for treatment of acute repetitive seizures; SAN2355 to treat resistant focal onset seizures; and SAN2465, a negative allosteric modulator to treat major depressive disorder. In addition, the company's other programs to treat epilepsy, Alzheimer's, schizophrenia, and migraine. It has research and collaboration agreements with Boehringer Ingelheim International GmbH to research, develop, manufacture, and commercialize therapeutics; license agreement with Productos Medix, S.A. de C.V. develop and commercialize tesofensine and/or Tesomet; research services agreement and a collaboration agreement with Cephagenix ApS to identify and develop novel migraine treatments; and research collaboration with AstronauTx to research, develop, manufacture, and commercialize therapeutics for Alzheimer's disease. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Sector:Healthcare
Industry:Biotechnology
Address:Murervangen 42, Glostrup, Denmark, 2600
Website:https://www.saniona.com
ISIN:SE0005794617
LEI:549300XO4L9XNOCFCZ84

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:7.48 
PEG Ratio:0.05 
Price to Sales:0.29 
Price to Book:0.18 
Profit Margin:0.43 
Operating Margin:0.71 
Return on Assets:0.24 
Return on Equity:0.41 
Revenue:434.4M 
EBITDA:280.78M 
Shares:138.03M 
Market Cap:118.98M 

TECHNICAL INDICATORS

MA5:0.842.5%
MA10:0.834.5%
MA20:0.833.4%
MA50:0.9813.1%
MA100:1.0825.1%
MA200:1.4163.4%
STO9:70.21
STO14:70.21
RSI14:52.45
WPR14:-29.79
MTM14:0.03
ROC14:0.04 
ATR:0.03 
Week High:0.904.1%
Week Low:0.7811.1%
Month High:0.904.1%
Month Low:0.7863.4%
Year High:2.58198.7%
Year Low:0.7811.1%